Editas Medicine Inc. (EDIT)
EDIT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/0001650664-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EDIT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001650664 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $40.5M |
| Net income | -$160.1M |
| Operating income | -$160.0M |
| Net margin | -395.0% |
| Operating margin | -394.9% |
| Revenue growth | +25.4% |
| Cash | $146.6M |
| Total assets | $186.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $93.2M cash; operating cash flow -$27.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 154,339,748 (2026-11-06); 97,618,660 a year earlier; 81,673,688 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2026-05-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $107K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.4M | -$23.4M | -$21.2M | $93.2M | $56.8M | $49.8M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $11.9M | -$18.2M | -$29.6M | $181.8M | $55.7M | $47.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $2.8M | -$25.0M | -$23.1M | $123.6M | $54.7M | $38.7M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $24.7M | -$5.6M | -$36.4M | $146.6M | $58.6M | $40.5M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $7.5M | -$25.1M | -$30.8M | $165.6M | $59.1M | $46.4M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $3.6M | -$53.2M | -$50.2M | $138.5M | $56.7M | $38.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $4.7M | -$76.1M | -$47.8M | $138.7M | $54.6M | $35.8M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $30.6M | -$45.4M | -$50.8M | $131.5M | $57.4M | $32.3M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-31 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 733 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.6% |
| 1 month | -11.2% |
| 3 months | -22.8% |
| Year to date | +5.9% |
| 1 year | -14.6% |
| From 52-week high | -42.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals Inc. | $2.83 | -9.29% | $289.0M |
| SCTX | Scribe Therapeutics Inc. | $15.37 | -6.05% | $291.1M |
| EIKN | Eikon Therapeutics Inc. | $5.38 | -9.95% | $291.8M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| AGMB | AgomAb Therapeutics NV | $5.97 | -6.13% | $294.0M |
| TRXB | TRex Bio Inc. | $10.77 | -21.21% | $295.6M |
| IPSC | Century Therapeutics Inc. | $1.64 | -0.61% | $297.8M |
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier